GSK looks to broaden Trelegy Ellipta use in the USA

3 October 2019

UK pharma major GlaxoSmithKline (LSE: GSK) and its US partner Innoviva (Nasdaq: INVA) have submitted to the US Food and Drug Administration (FDA) for approval to market Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) in a new indication.

The firms want to offer the once-daily, single-inhaler triple therapy for the treatment of asthma in adults, building on the September 2017 approval for chronic obstructive pulmonary disease (COPD). European approval for COPD was granted later in 2017.

Analysts have projected that approval in this indication could help push overall revenue for the product to $1.7 billion by 2023, although the existing COPD indication will likely drive the bulk of these sales.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK